InvestorsHub Logo
Followers 2
Posts 72
Boards Moderated 0
Alias Born 06/01/2012

Re: None

Thursday, 07/25/2013 10:43:25 AM

Thursday, July 25, 2013 10:43:25 AM

Post# of 54032
Tauriga Sciences Appoints ProActive Capital Group as Capital Markets & Digital Media Advisor


Tauriga Sciences, Inc. (OTCQB:TAUG), a diversified life sciences company focused on proprietary biotherapeutics and diagnostics, novel medical devices and consumer healthcare businesses, has today announced the appointment of ProActive Capital Group as its new Capital Markets Advisory and Digital Media Strategies firm. Tauriga will utilize ProActive Capital's well-established relationships with the investment communities to assist the company in fostering productive relationships with analysts, brokers, potential investors, and other financial professionals, as well as to manage its unique digital media program.
"As we continue to implement our growth strategy, we are very pleased to have retained the services of ProActive Capital Group, a leading life sciences advisory firm," Tauriga's CEO Seth M. Shaw stated. "ProActive Capital has an outstanding track record in helping to convey the value of biotech companies to the investment and media communities. We believe the timing is right to articulate our investment thesis to expand our reach and increase our visibility with key stakeholders. We look forward to embarking on a significant new and expanded strategy so that we can achieve a fair valuation that clearly reflects the intrinsic value of our scientific initiatives."

"We are delighted to have been selected by Tauriga Sciences, a leading company in the proprietary biotherapeutics and diagnostics market," stated Jeff Ramson, Founder and CEO of ProActive Capital Group. "We look forward to developing and implementing a quality capital markets and digital media strategy to increase Tauriga's visibility and build its brand among the key audience segments including the investment and media communities."

About Tauriga Sciences, Inc.

Tauriga Sciences, Inc. (TAUG) is a life sciences company that focuses on proprietary biotherapeutics and diagnostics, novel medical devices and consumer healthcare. The mission of the Company is to acquire and build a diversified portfolio of medical technology assets that is capital efficient and of significant value to the shareholders. The Company's business model includes the acquisition of licenses, equity stakes, rights on both an exclusive and non-exclusive basis, and entire businesses. Management is firmly committed to building lasting shareholder value in the short, intermediate, and long terms. The Company's new corporate website can be found at www.taurigasciences.com.

About ProActive Capital Group, LLC

ProActive Capital Group, LLC ("PCG") is dedicated to the discovery and creation of value, specifically in the emerging public company marketplace. PCG provides a unique service that combines capital market advisory services with traditional and social/digital media communications. The firm's overarching goal is to develop and maintain stakeholder awareness from all constituents in order to maximize shareholder value. PCG's capital market advisory services include key strategies to increase corporate transparency and credibility for companies across all sectors. The firm's communications services leverage traditional, digital and social media channels to further increase awareness through proprietary and best-of-breed media strategies. Communicating the client's story accurately and effectively to a wide but concentrated audience is tantamount to maximizing exposure to its current and potential shareholders. For more information: www.proactivecapital.com.

DISCLAIMER

Forward-Looking Statements: Except for statements of historical fact, this news release contains certain "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995, including, without limitation expectations, beliefs, plans and objectives regarding the development, use and marketability of products. Such forward-looking statements are based on present circumstances and on TAUG's predictions with respect to events that have not occurred, that may not occur, or that may occur with different consequences and timing than those now assumed or anticipated. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, and are not guarantees of future performance or results and involve risks and uncertainties that could cause actual events or results to differ materially from the events or results expressed or implied by such forward-looking statements. Such factors include general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to fund operations and other factors over which TAUG has little or no control. Such forward-looking statements are made only as of the date of this release, and TAUG assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. Readers should not place undue reliance on these forward-looking statements. Risks, uncertainties and other factors are discussed in documents filed from time to time by TAUG with the Securities and Exchange Commission.

This press release does not and shall not constitute an offer to sell or the solicitation of any offer to buy any of the securities, nor shall there be any sale of the securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state. The securities have not been registered under the Securities Act of 1933, as amended (the "Securities Act") or any state securities laws, and may not be offered or sold in the United States absent registration, or an applicable exemption from registration, under the Securities Act and applicable state securities laws.

CONTACT:

For further information regarding
Tauriga Sciences, Inc.
Mr. Seth M. Shaw
Chairman & Chief Executive Officer
Tauriga Sciences, Inc.
www.taurigasciences.com
New York: +1-917-796-9926
Montreal: +1-514-840-3697
Email: sshaw@tauriga.com

Investor Contact:
Adam Holdsworth
ProActive Capital
(646) 862-4607
adamh@proactivecapital.com

Media Contact:
Sandra Lee
ProActive Capital
(646) 862-4608
slee@proactivecapital.com
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.